Zobrazeno 1 - 10
of 108
pro vyhledávání: '"Ivana Pierri"'
Efficacy of nilotinib therapy in patient with CML diagnosed in pre-TKI era and resistant to imatinib
Publikováno v:
Clinical Management Issues, Vol 4, Iss 6S, Pp 23-26 (2015)
Here we report a case of a 32-year-old man, who was diagnosed as having chronic myeloid leukaemia in 1998. After cytoreduction with hydroxyurea, the patient was submitted to high dose chemotherapy with haemopoietic stem cells rescue and reinfusion, a
Externí odkaz:
https://doaj.org/article/d24ba0511381499eb63d76e17c4ab9ed
Autor:
Paolo Giannoni, Gabriella Pietra, Giorgia Travaini, Rodolfo Quarto, Genti Shyti, Roberto Benelli, Laura Ottaggio, Maria Cristina Mingari, Simona Zupo, Giovanna Cutrona, Ivana Pierri, Enrico Balleari, Alessandra Pattarozzi, Marco Calvaruso, Claudio Tripodo, Manlio Ferrarini, Daniela de Totero
Publikováno v:
Haematologica, Vol 99, Iss 6 (2014)
Hepatocyte growth factor, produced by stromal and follicular dendritic cells, and present at high concentrations in the sera of patients with chronic lymphocytic leukemia, prolongs the survival of leukemic B cells by interacting with their receptor,
Externí odkaz:
https://doaj.org/article/07ea0c7f2d5d44148e647c7e52803921
Autor:
Alessandra Musso, Silvia Catellani, Paolo Canevali, Sara Tavella, Roberta Venè, Silvia Boero, Ivana Pierri, Marco Gobbi, Annalisa Kunkl, Jean-Louis Ravetti, Maria Raffaella Zocchi, Alessandro Poggi
Publikováno v:
Haematologica, Vol 99, Iss 1 (2014)
In this study, we analyzed the influence of mesenchymal stromal cells derived from lymph nodes of non-Hodgkin’s lymphomas, on effector functions and differentiation of Vdelta (δ)2 T lymphocytes. We show that: i) lymph-node mesenchymal stromal cell
Externí odkaz:
https://doaj.org/article/cb1e4662a4f64ac5b332b43fc1ae0e0f
Publikováno v:
PLoS ONE, Vol 6, Iss 4, p e18925 (2011)
Imatinib mesylate is a first line treatment of Chronic Myelogenous Leukemia and of a rare form of gastrointestinal stromal cancer, where the response to the drug is also linked to the immune system activation with production of antineoplastic cytokin
Externí odkaz:
https://doaj.org/article/43a888f74f0d45ed92183b04cada8d05
Autor:
Michele Cea, Debora Soncini, Floriana Fruscione, Lizzia Raffaghello, Anna Garuti, Laura Emionite, Eva Moran, Mirko Magnone, Gabriele Zoppoli, Daniele Reverberi, Irene Caffa, Annalisa Salis, Antonia Cagnetta, Micaela Bergamaschi, Salvatore Casciaro, Ivana Pierri, Gianluca Damonte, Filippo Ansaldi, Marco Gobbi, Vito Pistoia, Alberto Ballestrero, Franco Patrone, Santina Bruzzone, Alessio Nencioni
Publikováno v:
PLoS ONE, Vol 6, Iss 7, p e22739 (2011)
Aberrant histone deacetylase (HDAC) activity is frequent in human leukemias. However, while classical, NAD(+)-independent HDACs are an established therapeutic target, the relevance of NAD(+)-dependent HDACs (sirtuins) in leukemia treatment remains un
Externí odkaz:
https://doaj.org/article/062b8d15ac464dd1a91dcf9b866139d6
Autor:
Francesca Palandri, Fausto Castagnetti, Ilaria Iacobucci, Giovanni Martinelli, Marilina Amabile, Gabriele Gugliotta, Angela Poerio, Nicoletta Testoni, Massimo Breccia, Monica Bocchia, Monica Crugnola, Giovanna Rege-Cambrin, Bruno Martino, Ivana Pierri, Franca Radaelli, Giorgina Specchia, Fabrizio Pane, Giuseppe Saglio, Gianantonio Rosti, Michele Baccarani
Publikováno v:
Haematologica, Vol 95, Iss 8 (2010)
Before the introduction of imatinib, interferon α-based regimens were the gold standard for treatment of early chronic phase chronic myeloid leukemia patients. The combination of IFN-α with imatinib is currently being investigated in at least two l
Externí odkaz:
https://doaj.org/article/241c9fb5fb6647e696e85aa7a336bb7d
Autor:
Michele Cea, Alessio Nencioni, Marco Gobbi, Santina Bruzzone, Alberto Ballestrero, Franco Patrone, Fabrizio Montecucco, Annalisa Salis, Gianluca Damonte, Chiara Zucal, Alessandro Provenzani, Luca Mastracci, Giulio Fraternali, Anna Garuti, Micaela Bergamaschi, Ivana Pierri, Sophia Adamia, Prakrati Acharya, Debora Soncini, Chirag Acharya, Irene Caffa, Antonia Cagnetta
Supplementary Figures legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0bfc9436539078a8a5ea068034b14f9
https://doi.org/10.1158/1078-0432.22457010
https://doi.org/10.1158/1078-0432.22457010
Autor:
Michele Cea, Alessio Nencioni, Marco Gobbi, Santina Bruzzone, Alberto Ballestrero, Franco Patrone, Fabrizio Montecucco, Annalisa Salis, Gianluca Damonte, Chiara Zucal, Alessandro Provenzani, Luca Mastracci, Giulio Fraternali, Anna Garuti, Micaela Bergamaschi, Ivana Pierri, Sophia Adamia, Prakrati Acharya, Debora Soncini, Chirag Acharya, Irene Caffa, Antonia Cagnetta
Purpose: The nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, APO866, has been previously shown to have antileukemic activity in preclinical models, but its cytotoxicity in primary leukemia cells is frequently limited. The success of current
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::954c16f91787ef7e71a406ebc1314547
https://doi.org/10.1158/1078-0432.c.6523482.v1
https://doi.org/10.1158/1078-0432.c.6523482.v1
Autor:
Michele Cea, Alessio Nencioni, Marco Gobbi, Santina Bruzzone, Alberto Ballestrero, Franco Patrone, Fabrizio Montecucco, Annalisa Salis, Gianluca Damonte, Chiara Zucal, Alessandro Provenzani, Luca Mastracci, Giulio Fraternali, Anna Garuti, Micaela Bergamaschi, Ivana Pierri, Sophia Adamia, Prakrati Acharya, Debora Soncini, Chirag Acharya, Irene Caffa, Antonia Cagnetta
Supplemental Figures 1-8. Figure 1S: A) Nampt locus (human chromosome 7q22.3) copy number heatmap for lines included in the Cancer Cell Line Encyclopedia. B) mRNA Nampt expression plotted vs. DNA copy number (log2 ratio). Figure 2S: effect of APO866
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3de3ca17d58de553a14d13331555ac3a
https://doi.org/10.1158/1078-0432.22457013
https://doi.org/10.1158/1078-0432.22457013
Efficacy of nilotinib therapy in patient with CML diagnosed in pre-TKI era and resistant to imatinib
Publikováno v:
Clinical Management Issues; Vol 4, No 6S (2010); 23-26
Clinical Management Issues, Vol 4, Iss 6S, Pp 23-26 (2015)
Clinical Management Issues, Vol 4, Iss 6S, Pp 23-26 (2015)
Here we report a case of a 32-year-old man, who was diagnosed as having chronic myeloid leukaemia in 1998. After cytoreduction with hydroxyurea, the patient was submitted to high dose chemotherapy with haemopoietic stem cells rescue and reinfusion, a